FindMyKOL

Tonga Nfor, MD

Basic profile

Aurora St. Luke's Medical Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionMilwaukee, WI · MidwestSpecialtyInterventional CardiologyFocusCardiology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Tonga Nfor is a Cardiology physician affiliated with Aurora St. Luke's Medical Center. OpenAlex indexes 65 publications with 432 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
65publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

432citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Boston Scientific Corporation
    Program year20252 payments
    $127
  • Penumbra, Inc.
    Program year20251 payment
    $70
  • ABIOMED
    Program year20241 payment
    $112
All 7 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    80.9%
    Beta blocker19.3%
    Metoprolol Succinate56%Carvedilol24%Metoprolol Tartrate15%Atenolol3%Labetalol Hcl2%
    Part D<11 patients
    Statin18%
    Atorvastatin Calcium82%Rosuvastatin Calcium12%Pravastatin Sodium5%Simvastatin2%
    Part D<11 patients

    + 21 more classes in this area

  • Blood & clotting

    13.8%
    P2Y12 inhibitor6.5%
    Clopidogrel85%Brilinta10%Prasugrel Hcl5%
    Part D<11 patients
    Factor Xa inhibitor5.4%
    Eliquis78%Xarelto22%
    Part D≥79 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    4.8%
    Potassium supplement1.8%
    Potassium Chloride100%
    Part D≥35 patients
    SGLT2 inhibitor1.5%
    Jardiance100%
    Part D≥34 patients

    + 2 more classes in this area

Where care is delivered (Part B)31.4% facility · 68.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”